[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:erbb3-wt-allele":3},{"name":4,"total":5,"recruiting":6,"trials":7},"ERBB3 wt Allele",5,4,[8,16,23,30,36],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05142189","Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer",[12],"Phase 1","RECRUITING","2026-08-26T02:16:32.589113Z","2026-07-24T01:27:14.869513Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06941272","A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C\u002FLIGHTBEAM-U01)",[20],"Phase 1\u002FPhase 2","2026-08-26T02:16:28.221034Z","2026-07-19T19:36:05.059044Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT04348747","Dendritic Cell Vaccines Against Her2\u002FHer3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer",[27],"Phase 2","2026-08-26T02:15:14.574786Z","2026-07-05T05:32:16.794666Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT07070232","A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors",[20],"2026-08-26T02:18:30.351130Z","2026-07-24T01:27:14.894336Z",{"nct_id":37,"title":38,"phases":39,"status":40,"updated_at":41,"content_modified":42},"NCT07729046","Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+\u002FHER2- Breast Cancer",[27],"NOT_YET_RECRUITING","2026-08-26T02:15:38.131683Z","2026-07-30T01:46:14.449733Z"]